3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
8
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
92
Nivolumab
57
Cyclophosphamide
22
Ipilimumab
17
atezolizumab
15
Magnetic Resonance Spectroscopy
14
Specimen Handling
13
Radiosurgery
13
Paclitaxel
13
Interleukin-2
12
Docetaxel
12
fludarabine
11
Carboplatin
11
Pemetrexed
10
spartalizumab
9
Biopsy
9
durvalumab
8
Cisplatin
8
Radiotherapy
7
Immune Checkpoint Inhibitors
7
Blood Specimen Collection
7
cemiplimab
6
avelumab
6
aldesleukin
6
Taxes
6
Gemcitabine
6
Drug Therapy
6
Bevacizumab
6
trametinib
5
tislelizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Colony-Stimulating Factors
×
Thoracic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled